The FDA also posted this article on the “launch of the FDA rare disease innovation hub”, here is the link. https://www.linkedin.com/posts/fda_rare-disease-innovation-hub-activity-7221533745525178372-XtiS?utm_source=share&utm_medium=member_ios
I wonder if the delays in PTX-100 have anything to do with this rare disease endpoint advancement (RDEA) pilot program? Sure would be a terrific fit given it ticks all the boxes. The timing of PTX-100 going into phase 2 with the launch of this pilot program could be the stars aligning for prescient therapeutics, let’s hope so!
